New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annu...(The Annual Meeting of the American Psych...),Health

(4) Joyce M, Khan A, Atkinson S, et al. Efficacy and safety of extended release Quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorder (GAD) [poster]. Presented at: The Annual Meeting of the American Psychiatric Association; May 3-8, 2008, Washington, D.C., USA.

(5) Katzman M, Brawman-Mintzer O, Reyes E, et al. Extended release quetiapine fumarate (quetiapine XR) monotherapy in maintenance treatment of generalized anxiety disorder (GAD): efficacy and tolerability results from a randomized, placebo-controlled trial

[poster]. Presented at: The Annual Meeting of the American Psychiatric Association; May 3-8, 2008, Washington, D.C., USA.

(6) National Alliance on Mental Illness: Major Depression Fact Sheet. 2007. Available at: http://www.nami.org/Template.cfm?Section=By_Illness&Template=/TaggedPage/Ta gge dPageDisplay.cfm&TPLID=54&ContentID=26414. Accessed November 30, 2007.

(7) Nemeroff, CB. Prevalence and Management of Treatment-Resistant Depression. J Clin Psychiatry. 2007; 68:17-25.

(8) National Institute of Mental Health: Anxiety Disorders. NIH Publication No. 06-3879. Available at: http://www.nimh.nih.gov/health/publications/anxiety-disorders/generalized- anxiety-disorder-gad.shtml Accessed March 20, 2008.

(9) Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000: 472- 475.

(10) Rickels K. and Rynn M. Pharmacotherapy of Generalized Anxiety Disorder. J Clin Psychiatry. 2002;63(suppl 14): 9-16.

(11) Data on file, DA-SXR-12, AstraZeneca LP.

(12) Lundbeck Institute. Psychiatric
'/>"/>